Advertisement

Topics

Amgen's biosimilar Avastin gains positive opinion from EMA panel

06:11 EST 13 Nov 2017 | SmartBrief

Amgen's ABP 215, a biosimilar of Avastin, or bevacizumab, was recommended by the European Medicines Agency's Committee for Me -More

Original Article: Amgen's biosimilar Avastin gains positive opinion from EMA panel

NEXT ARTICLE

More From BioPortfolio on "Amgen's biosimilar Avastin gains positive opinion from EMA panel"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...